Engineered immune cells take aim at tough blood cancers
NCT ID NCT07345780
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new treatment using the body's own immune cells, called CAR-T cells, to fight certain blood cancers (like T-cell leukemia/lymphoma) that have returned or not responded to standard therapy. The study will enroll about 20 to 28 adults aged 18-85. The main goals are to check if the treatment is safe and to see how well it works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CD7-POSITIVE HEMATOLOGICAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental CAR-T therapy takes on tough leukemia
- Can lab tests guide better AML treatment choices?
- New transplant combo aims to outsmart relapsed leukemia
- Immune cells engineered to hunt cancer: new trial for hard-to-treat blood cancers
- New drug cocktail aims to beat back tough leukemia
- 15-Year safety check for caribou cell therapy patients